ADAR1 Capital Management »

Immatics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Immatics (IMTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Immatics

Tip: Access up to 7 years of quarterly data

All positions including Immatics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immatics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $170k 16k 10.51
2023-12-31 $232k 22k 10.53

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Immatics

Perceptive Advisors
T. Rowe Price Investment Management
Baker Bros. Advisors
Paradigm Biocapital Advisors
Vestal Point Capital
T. Rowe Price Associates
Woodline Partners
Citadel Advisors
OrbiMed Advisors
Goldman Sachs Group
RA Capital Management
Braidwell
Frazier Life Sciences Management
Suvretta Capital Management
Daniel D. Thurber

View all funds holding Immatics